OpenLegislation

Regulation 211 Amendment of regulation 279 (products without a marketing authorisation)I1F1

United Kingdom

For regulation 279 substitute—

“279.
(1)

A person may not publish an advertisement in Great Britain for a medicinal product unless one of the following is in force for the product—

(a)

a UKMA(GB) or UKMA(UK);

(b)

a COR(GB) or COR(UK); or

(c)

a THR(GB) or THR(UK).

(2)

A person may not publish an advertisement in Northern Ireland for a medicinal product unless one of the following is in force for the product—

(a)

a UKMA(NI) or UKMA(UK);

(b)

a COR(NI) or COR(UK);

(c)

a THR(NI) or THR(UK);

(d)

an EU marketing authorisation; or

(e)

an Article 126a authorisation.

(3)

A person may not publish an advertisement in the whole United Kingdom for a medicinal product unless, in relation to that product—

(a)

one of the authorisations or registrations specified in paragraph (1) is in force in Great Britain; and

(b)

one of the authorisations or registrations specified in paragraph (2) is in force in Northern Ireland.”.

Annotations

Textual amendments

F1

Reg. 211 substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 167

Commencement

I1

Reg. 211 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1